• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度国家心力衰竭登记处按疾病病因划分的一年死亡率和再入院率。

One-year mortality and re-admission rate by disease etiology in National Heart Failure Registry of India.

作者信息

Harikrishnan Sivadasanpillai, Bahl Ajay, Roy Ambuj, Mishra Animesh, Prajapati Jayesh, Manjunath C N, Sethi Rishi, Guha Santanu, Satheesh Santhosh, Dhaliwal R S, Sharma Meenakshi, Ganapathy Sanjay, Jeemon Panniyammakal

机构信息

Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum, India.

Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

出版信息

Nat Commun. 2025 Jan 2;16(1):275. doi: 10.1038/s41467-024-55362-z.

DOI:10.1038/s41467-024-55362-z
PMID:39746979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11697269/
Abstract

Survival outcomes of patients with heart failure (HF) based on their disease etiology are not well described. Here, we provide one-year mortality outcomes of 10850 patients with HF (mean age = 59.9 years, 31% women) in India. Ischemic heart disease (71.9%), dilated cardiomyopathy (17.3), rheumatic heart disease (5.4), non-rheumatic valvular heart disease (1.9), hypertrophic cardiomyopathy (0.8), congenital heart disease (0.7), peri-partum cardiomyopathy (0.5), restrictive cardiomyopathy (0.4), and infective endocarditis (0.1) were the main disease etiologies. Mortality rate per 100-person years of follow-up varied from 13.8 (95% CI: 6.2-30.7) in peri-partum cardiomyopathy to 92.9 (46.5-185.9) in infective endocarditis. Compared to ischemic heart disease, the mortality was two to five times higher in rheumatic heart disease (HR = 2.0; 95% CI: 1.6-2.4), congenital heart disease (2.9; 1.9-4.2), and infective endocarditis (4.8; 2.4-9.8). The wide variations in mortality rate in HF patients may bring possible clinical applicability of risk stratification.

摘要

基于病因的心力衰竭(HF)患者的生存结果尚无充分描述。在此,我们提供了印度10850例HF患者(平均年龄59.9岁,31%为女性)的一年死亡率结果。缺血性心脏病(71.9%)、扩张型心肌病(17.3%)、风湿性心脏病(5.4%)、非风湿性瓣膜性心脏病(1.9%)、肥厚型心肌病(0.8%)、先天性心脏病(0.7%)、围产期心肌病(0.5%)、限制性心肌病(0.4%)和感染性心内膜炎(0.1%)是主要病因。每100人年随访的死亡率从围产期心肌病的13.8(95%CI:6.2 - 30.7)到感染性心内膜炎的92.9(46.5 - 185.9)不等。与缺血性心脏病相比,风湿性心脏病(HR = 2.0;95%CI:1.6 - 2.4)、先天性心脏病(2.

相似文献

1
One-year mortality and re-admission rate by disease etiology in National Heart Failure Registry of India.印度国家心力衰竭登记处按疾病病因划分的一年死亡率和再入院率。
Nat Commun. 2025 Jan 2;16(1):275. doi: 10.1038/s41467-024-55362-z.
2
Etiology of Heart Failure Across the Ejection Fraction Spectrum and Association With Prognosis.射血分数范围内心力衰竭的病因及其与预后的关联
JACC Heart Fail. 2025 Aug;13(8):102491. doi: 10.1016/j.jchf.2025.03.037. Epub 2025 Jun 16.
3
Prognostic impact of iron deficiency in new-onset chronic heart failure: Danish Heart Failure Registry insights.缺铁对新发慢性心力衰竭的预后影响:丹麦心力衰竭登记研究的见解
ESC Heart Fail. 2025 Apr;12(2):1346-1357. doi: 10.1002/ehf2.15149. Epub 2024 Nov 6.
4
[Disease burden and clinical status of congenital heart disease combined with heart failure in China: a survey and analysis].[中国先天性心脏病合并心力衰竭的疾病负担与临床状况:一项调查与分析]
Zhonghua Er Ke Za Zhi. 2025 Feb 2;63(2):148-156. doi: 10.3760/cma.j.cn112140-20241031-00772.
5
Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization.心力衰竭住院后死亡率或再入院风险预测指数的比较性能
ESC Heart Fail. 2025 Apr;12(2):1227-1236. doi: 10.1002/ehf2.15129. Epub 2025 Jan 21.
6
Contemporary Profile and In-Hospital Outcomes of Decompensated Heart Failure in a Semi-Rural Setting in Cameroon: The Buea Heart Study.喀麦隆半农村地区失代偿性心力衰竭的当代概况及院内结局:布埃亚心脏研究
Glob Heart. 2025 Jun 23;20(1):56. doi: 10.5334/gh.1442. eCollection 2025.
7
Beta-blockers in patients without heart failure after myocardial infarction.心肌梗死后无心力衰竭的患者使用β受体阻滞剂。
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565. doi: 10.1002/14651858.CD012565.pub2.
8
Prevalence, Characteristics, and Outcomes of Infective Endocarditis Readmissions in Patients With Variables Associated With Liver Disease in the United States.美国伴有肝病相关变量的患者感染性心内膜炎再入院的患病率、特征及结局
Angiology. 2025 Jul;76(6):538-545. doi: 10.1177/00033197241227502. Epub 2024 Jan 12.
9
Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study).来自 14 个中低收入国家的 3343 名儿童和成人风湿性心脏病患者的临床结局:全球风湿性心脏病登记研究(REMEDY 研究)的两年随访。
Circulation. 2016 Nov 8;134(19):1456-1466. doi: 10.1161/CIRCULATIONAHA.116.024769. Epub 2016 Oct 4.
10
Exercise-based rehabilitation for heart failure.基于运动的心力衰竭康复治疗
Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD003331. doi: 10.1002/14651858.CD003331.pub4.

本文引用的文献

1
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.2023 年 ESC 急性和慢性心力衰竭诊断和治疗指南的重点更新:由欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断和治疗工作组制定,ESC 心力衰竭协会(HFA)特别贡献。
Eur J Heart Fail. 2024 Jan;26(1):5-17. doi: 10.1002/ejhf.3024. Epub 2024 Jan 3.
2
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease.2023 年世界心脏联盟风湿性心脏病超声心动图诊断指南。
Nat Rev Cardiol. 2024 Apr;21(4):250-263. doi: 10.1038/s41569-023-00940-9. Epub 2023 Nov 2.
3
Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summary.风湿性心脏病的三级预防与治疗:美国国立心肺血液研究所工作组总结。
BMJ Glob Health. 2023 Oct;8(Suppl 9). doi: 10.1136/bmjgh-2023-012355.
4
New Insights into Mortality-Related Risk Factors in Infective Endocarditis: Results from the Brandenburg State Endocarditis Register.感染性心内膜炎相关死亡率的新见解:勃兰登堡州心内膜炎注册中心的结果。
Thorac Cardiovasc Surg. 2024 Dec;72(8):587-594. doi: 10.1055/a-2199-2344. Epub 2023 Oct 26.
5
Outcomes at one year in women with peripartum cardiomyopathy: Findings from the ESC EORP PPCM Registry.围生期心肌病女性患者的一年期结局:ESC EORP PPCM 注册研究结果。
Eur J Heart Fail. 2024 Jan;26(1):34-42. doi: 10.1002/ejhf.3055. Epub 2023 Oct 31.
6
Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America.心力衰竭流行病学与结局统计:美国心力衰竭学会报告
J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26.
7
Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry.印度 10851 例心力衰竭患者的临床特征和 90 天结局:国家心力衰竭注册研究。
ESC Heart Fail. 2022 Dec;9(6):3898-3908. doi: 10.1002/ehf2.14096. Epub 2022 Aug 10.
8
Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality.基于病因的心力衰竭死亡原因:全因死亡率和心血管死亡率的长期队列研究
J Clin Med. 2022 Jan 31;11(3):784. doi: 10.3390/jcm11030784.
9
Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy.长期与近期起病扩张型心肌病的预后差异。
ESC Heart Fail. 2022 Apr;9(2):1294-1303. doi: 10.1002/ehf2.13816. Epub 2022 Feb 7.
10
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.肥厚型心肌病的管理:美国心脏病学会的最新综述。
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021.